Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes. (May 2017)

• Record Type: Journal Article
• Authors: Bharadwaj, Gaurav; Nhan, Viet; Yang, ShanChao; Li, Xiaocen; Narayanan, Anand; Macarenco, Ana Carolina; Shi, Yu; Yang, Darrion; Vieira, Letícia Salvador; Xiao, Wenwu; Li, Yuanpei; Lam, Kit S
• Is Part Of: Nanomedicine. Volume 12:Number 10(2017)
• Page Start: 1153
• Page End: 1164
• Publication Date: 2017-05
• Subjects: cabazitaxel -- cholic acid -- docetaxel -- drug delivery -- micelle -- nanoparticle -- paclitaxel -- taxane -- telodendrimer; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2017-0361
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG 5K -CA8 ) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family.Materials & methods: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method.Results: Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1–6 μM), better hematocompatibility and lack of in vitro cytotoxicity.Conclusion: Along with PEG 5K -CA8, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.